tiprankstipranks
Immunocore Reveals Promising Brenetafusp Trial Results
Company Announcements

Immunocore Reveals Promising Brenetafusp Trial Results

Don't Miss our Black Friday Offers:

An update from Immunocore Holdings (IMCR) is now available.

Immunocore Holdings plc announced promising results from its Phase 1 trial of a new cancer treatment, brenetafusp, for melanoma patients previously treated with immune checkpoints. The findings are set to be presented at the ASCO Annual Meeting and will be further discussed in a conference call and webcast. Investors and interested parties can access the webcast via the company’s website to learn about the potential impact on melanoma treatment.

For an in-depth examination of IMCR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmunocore downgraded to Neutral from Outperform at Mizuho
TipRanks Auto-Generated NewsdeskImmunocore Holdings Prepares Early Loan Agreement Termination
TipRanks Auto-Generated NewsdeskImmunocore Holdings Plc Reports Strong Q3 Revenue Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App